Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

174.86 +4.13 (+2.42%)
Delayed Quote Updated: 1:46 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Reasons GH is risky and 1 stock to buy instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid qu... 
Via StockStory
Topics Bankruptcy Supply Chain
News headline image
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
From Guardant Health, Inc.
Via Business Wire
Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗
Via Chartmill
News headline image
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
From Guardant Health, Inc.
Via Business Wire
News headline image
3 of Wall Street’s Favorite Stocks That Fall Short
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Cash-Burning Stocks with Questionable Fundamentals
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy Supply Chain
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Question
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
Topics Credit Cards
News headline image
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a... 
Via StockStory
News headline image
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Business Insider Names Guardant Health One of America's Most Innovative Businesses
From Guardant Health, Inc.
Via Business Wire
News headline image
1 Growth Stock to Add to Your Roster and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Rule Breakers Buy a Stock That's Already "Won" ↗
You found a great company, then watched it double before you got round to buying. 
Via The Motley Fool
Topics Death
News headline image
Guardant Health to Appeal Federal District Court Judgment
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗
Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs... 
Via MarketBeat
News headline image
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗
Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗
Shield screening volumes more than doubled, with UnitedHealth coverage now active. 
Via The Motley Fool
Topics Earnings
News headline image
2 Cash-Burning Stocks to Target This Week and 1 We Find Risky
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh... 
Via StockStory
Topics Energy
News headline image
GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth
Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $33... 
Via StockStory
News headline image
Guardant Health Q2 Earnings Call Highlights ↗
Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses.... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.